

1. Please click [here](#) [1] to download the group picture of your seminar.

2. Presentations:

1. Therapeutic drug monitoring for all drugs and for all patients? [2]

*Dr Ute Blassmann* [3], *Heidelberg University Hospital, Germany*

2. Do we need therapeutic drug monitoring for beta lactams or can we just use prolonged infusions? [4]

*Dr Ute Blassmann* [3], *Heidelberg University Hospital, Germany*

3. The impact of PK/PD for clinical decisions [5]

*Dr Anouk Muller* [6], *HaaglandenMC, The Hague and ErasmusMC, Rotterdam*

4. MIC directed therapy: why, when and what are the pitfalls? [7]

*Dr Anouk Muller* [6], *HaaglandenMC, The Hague and ErasmusMC, Rotterdam*

5. Interactive Part – clinical cases – PK/PD [8]

*Prof Dr Isabel Spriet* [9], *UZ Leuven, Belgium*

*Dr Peter Declercq* [10], *University Hospitals Leuven, Belgium*

6. Implementation of check of medication appropriateness: what can the computer do for ABS? [11]

*Prof Dr Isabel Spriet* [9], *UZ Leuven, Belgium*

7. Antifungal therapy: what comes out of the pipeline in the near future? [12]

*Prof William Hope\** [13], *University of Liverpool, United Kingdom*

8. TDM and PK/PD in antifungal therapy: when and why? [14]

*Prof William Hope\** [13], *University of Liverpool, United Kingdom*

9. Antimicrobial prophylaxis in HSCT-patients: guidelines and evidence [15]

*Dr Philipp Wohlfarth* [16], *Medical University of Vienna, Austria*

10. Hygiene measures, isolation and therapy [17]

*Prof Dr Annette Schuermans* [18], *University Hospitals Leuven, Belgium*

11. What's really new in antibiotic therapy [19]

*Prof Dr Martin J. Hug* [20], *Institute of Pharmaceutical Sciences, University of Freiburg,*

Germany

## 12. Interactive Part - PKPD & TDM of antifungals <sup>[21]</sup>

*Prof Dr Isabel Spriet* <sup>[9]</sup>, *UZ Leuven, Belgium*

*Prof William Hope* <sup>[13]</sup>, *University of Liverpool, United Kingdom*

Last update: 25 September 2019

---

### Links

[1] [https://www.eahp.eu/sites/default/files/s1\\_2.png](https://www.eahp.eu/sites/default/files/s1_2.png) [2]

[https://www.eahp.eu/sites/default/files/1.\\_therapeutic\\_drug\\_monitoring\\_for\\_all\\_drugs\\_and\\_for\\_all\\_patients.pdf](https://www.eahp.eu/sites/default/files/1._therapeutic_drug_monitoring_for_all_drugs_and_for_all_patients.pdf)

[3] <http://www.eahp.eu/content/dr-ute-blasmann> [4]

[https://www.eahp.eu/sites/default/files/2.\\_do\\_we\\_need\\_therapeutic\\_drug\\_monitoring\\_for\\_beta\\_lactams\\_or\\_can\\_we](https://www.eahp.eu/sites/default/files/2._do_we_need_therapeutic_drug_monitoring_for_beta_lactams_or_can_we)

[5] [https://www.eahp.eu/sites/default/files/3.\\_the\\_impact\\_of\\_pkpd\\_for\\_clinical\\_decisions\\_0.pdf](https://www.eahp.eu/sites/default/files/3._the_impact_of_pkpd_for_clinical_decisions_0.pdf) [6]

<https://www.eahp.eu/content/dr-anouk-muller> [7]

[https://www.eahp.eu/sites/default/files/4.\\_mic\\_directed\\_therapy\\_why\\_when\\_and\\_what\\_are\\_the\\_pitfalls.pdf](https://www.eahp.eu/sites/default/files/4._mic_directed_therapy_why_when_and_what_are_the_pitfalls.pdf)

[8] [https://www.eahp.eu/sites/default/files/5.\\_interactive\\_part\\_-\\_clinical\\_cases\\_-\\_pkpd.pdf](https://www.eahp.eu/sites/default/files/5._interactive_part_-_clinical_cases_-_pkpd.pdf) [9]

<http://www.eahp.eu/content/prof-dr-isabel-spriet> [10] <http://www.eahp.eu/content/dr-peter-declercq> [11]

[https://www.eahp.eu/sites/default/files/6.\\_implementation\\_of\\_check\\_of\\_medication\\_appropriateness\\_what\\_can\\_the](https://www.eahp.eu/sites/default/files/6._implementation_of_check_of_medication_appropriateness_what_can_the)  
[12]

[https://www.eahp.eu/sites/default/files/7.\\_antifungal\\_therapy\\_what\\_comes\\_out\\_of\\_the\\_pipeline\\_in\\_the\\_near\\_future](https://www.eahp.eu/sites/default/files/7._antifungal_therapy_what_comes_out_of_the_pipeline_in_the_near_future)

[13] <http://www.eahp.eu/content/prof-william-hope> [14]

[https://www.eahp.eu/sites/default/files/8.\\_tdm\\_and\\_pkpd\\_in\\_antifungal\\_therapy\\_when\\_and\\_why.pdf](https://www.eahp.eu/sites/default/files/8._tdm_and_pkpd_in_antifungal_therapy_when_and_why.pdf) [15]

[https://www.eahp.eu/sites/default/files/9.\\_antimicrobial\\_prophylaxis\\_in\\_hscptpatients\\_guidelines\\_and\\_evidence.pdf](https://www.eahp.eu/sites/default/files/9._antimicrobial_prophylaxis_in_hscptpatients_guidelines_and_evidence.pdf)

[16] <http://www.eahp.eu/content/dr-philipp-wohlfarth> [17]

[https://www.eahp.eu/sites/default/files/10.\\_hygiene\\_measures\\_isolation\\_and\\_therapy.pdf](https://www.eahp.eu/sites/default/files/10._hygiene_measures_isolation_and_therapy.pdf) [18]

<http://www.eahp.eu/content/prof-dr-annette-schuermans> [19]

[https://www.eahp.eu/sites/default/files/11.\\_whats\\_reallly\\_new\\_in\\_antibiotic\\_therapy\\_mjh.pdf](https://www.eahp.eu/sites/default/files/11._whats_reallly_new_in_antibiotic_therapy_mjh.pdf) [20]

<http://www.eahp.eu/content/prof-dr-martin-j-hug-0> [21]

[https://www.eahp.eu/sites/default/files/12.\\_interactive\\_part\\_-\\_pkpd\\_tdm\\_of\\_antifungals.pdf](https://www.eahp.eu/sites/default/files/12._interactive_part_-_pkpd_tdm_of_antifungals.pdf)